Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Wiley Online Library.

Article  PubMed  Google Scholar 

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol Elsevier. 2022;77:1598–606.

Article  Google Scholar 

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019. Elsevier.

Article  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Am Soc Clin Oncol. J Clin Oncol. 2021;39(3_suppl):267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267.

Fulgenzi CAM, Cheon J, D’Alessio A, Nishida N, Ang C, Marron TU, et al. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer Elsevier. 2022;175:204–13.

Article  CAS  Google Scholar 

Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for hepatocellular carcinoma: a guide for hepatologists. Hepatology. 2022;75:1604–26 United States.

Article  PubMed  Google Scholar 

Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of hcc. Cancers (Basel). 2021;13:1962. Multidisciplinary Digital Publishing Institute.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72. https://doi.org/10.1038/s41571-021-00573-2.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745. Massachusetts Medical Society.

Article  CAS  PubMed  Google Scholar 

Fang P, Hu J, Cheng Z, Liu Z, Wang J, Jiao S. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012;7:e49717. Public Library of Science San Francisco, USA.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ollivier-Hourmand I, Allaire M, Cervoni JP, Weil D, Ozenne V, Rautou PE, et al. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma. J Hepatol: Elsevier; 2022.

Book  Google Scholar 

Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573 Nature Publishing Group.

Article  CAS  PubMed  Google Scholar 

Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61:526–36. Wiley Online Library.

Article  PubMed  Google Scholar 

Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. UEG J. 2022;10(1):41–53. https://doi.org/10.1002/ueg2.12188.

Article  CAS  Google Scholar 

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII–Renewing consensus in portal hypertension. J Hepatol Elsevier. 2022;76:959–74.

Article  Google Scholar 

Kihira S, Kagen AC, Vasudevan P, Jajamovich GH, Schiano TD, Andrle A-F, et al. Non-invasive prediction of portal pressures using CT and MRI in chronic liver disease. Abdom Radiol Springer. 2016;41:42–9.

Article  Google Scholar 

Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol. Frontiers. 2021;11:2205.

Google Scholar 

Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology Elsevier. 2008;134:1908–16.

Article  Google Scholar 

Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization. J Gastroenterol Hepatol. 2018;33:1397–406. Wiley Online Library.

Article  PubMed  Google Scholar 

Choi JW, Chung JW, Lee DH, Kim H-C, Hur S, Lee M, et al. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol. 2018;28:2184–93. https://doi.org/10.1007/s00330-017-5145-9.

Article  PubMed  Google Scholar 

Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245–56. Wiley Online Library.

Article  CAS  PubMed  Google Scholar 

Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol Elsevier. 2009;51:865–73.

Article  CAS  Google Scholar 

Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One. 2011;6:e16978. Public Library of Science San Francisco, USA.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol Springer. 2012;47:1030–5.

Article  CAS  Google Scholar 

Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma–a pilot study. Aliment Pharmacol Ther. 2012;35:83–91. Wiley Online Library.

Article  CAS  PubMed  Google Scholar 

Procopet B, Bureau C, Peron JM. sorafenib in portal hypertension. Aliment Pharmacol Ther. 2012;36:994. Wiley Online Library.

Article  CAS  PubMed  Google Scholar 

Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses…. Liver Int. 2021;41:1734–43. Wiley Online Library.

Article  PubMed  Google Scholar 

Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol Elsevier. 2014;60:969–74.

Article  Google Scholar 

Qi X, An W, Liu F, Qi R, Wang L, Liu Y, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension. Radiology. 2019;290:370–7. Radiological Society of North America.

Article  PubMed  Google Scholar 

Liu Y, Tang T, Huang Y, Ji J, Yu Q, Meng X, et al. Non-invasive score using non-contrast-enhanced MRI for identification of clinically significant portal hypertension (CHESS1802): a prospective, multicentre study. Lancet. 2019;394:S75. Elsevier.

Article  Google Scholar 

Humpire-Mamani GE, Bukala J, Scholten ET, Prokop M, van Ginneken B, Jacobs C. Fully automatic volume measurement of the spleen at ct using deep learning. Radiol Artif Intell. 2020;2:e190102. Radiological Society of North America.

Article  PubMed  PubMed Central  Google Scholar 

Linguraru MG, Sandberg JK, Jones EC, Summers RM. Assessing splenomegaly: automated volumetric analysis of the spleen. Acad Radiol Elsevier. 2013;20:675–84.

Article  Google Scholar 

Müller L, Kloeckner R, Mähringer-Kunz A, Stoehr F, Düber C, Arnhold G, et al. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol. 2022. https://doi.org/10.1007/s00330-022-08737-z.

Nuffer Z, Marini T, Rupasov A, Kwak S, Bhatt S. The best single measurement for assessing splenomegaly in patients with cirrhotic liver morphology. Acad Radiol Elsevier. 2017;24:1510–6.

Article  Google Scholar 

留言 (0)

沒有登入
gif